Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus
Table 1
Clinical characteristics of the patients before and after intervention.
Week 0
Week 52
value
Weight (kg)
69.23 ± 9.69
69.13 ± 9.62
0.816
BMI (kg/m2)
25.50 ± 2.14
25.46 ± 1.91
0.825
SBP (mmHg)
126.16 ± 12.51
130.25 ± 11.32
0.138
DBP (mmHg)
79.40 ± 8.25
82.08 ± 8.15
0.132
Hemoglobin (g/L)
140.62 ± 28.46
146.05 ± 11.88
0.405
ALT (U/L)
18.32 ± 6.26
21.52 ± 10.02
0.027
AST (U/L)
17.32 ± 2.91
29.96 ± 5.44
0.012
Creatinine (μmol/L)
67.64 ± 11.59
69.36 ± 14.89
0.359
eGFR (mL/min/1.73 m2)
98.71 ± 22.89
96.05 ± 21.27
0.351
Total cholesterol (mmol/L)
4.68 ± 0.98
5.05 ± 1.14
0.028
HDL-C (mmol/L)
1.16 ± 0.24
1.26 ± 0.27
0.008
LDL-C (mmol/L)
2.72 ± 0.79
2.93 ± 1.00
0.234
Triglycerides (mmol/L)
1.82 ± 1.37
2.04 ± 1.33
0.046
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; ALT: alanine aminotransferase; AST: aspartate transaminase; eGFR: estimated glomerular filtration rate; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol. All data are shown as mean ± SD.
